Paediatric onset lymphomatoid papulosis: results of a multicentre retrospective cohort study, on behalf of the EORTC Cutaneous Lymphoma Tumours Group (CLTG).


Journal

The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041

Informations de publication

Date de publication:
10 Apr 2024
Historique:
received: 14 12 2023
revised: 23 03 2024
accepted: 09 04 2024
medline: 10 4 2024
pubmed: 10 4 2024
entrez: 10 4 2024
Statut: aheadofprint

Résumé

Lymphomatoid Papulosis (LyP) is a rare cutaneous T-cell lymphoproliferative disorder. Comprehensive data on LyP in the paediatric population is scarce. To characterize epidemiological, clinical, histopathological, and prognostic features of paediatric LyP. This was a retrospective, multicentre international cohort study including 87 cases of children and adolescents with LyP diagnosed between 1998 and 2022. Patients aged ≤ 18 years old at disease onset were included. Diagnosis was made in each centre based on clinical-pathological correlation. Eighty-seven patients from 12 centres were included. The mean age at onset was 7.0 years (range 3 months-18 years) with a male to female ratio of 2:1. The mean time between onset of first cutaneous lesions and diagnosis was 1.3 years (range 0-14 years). Initial misdiagnosis concerned 26.4% of patients. Initially, LyP was most often misdiagnosed as Pityriasis lichenoides et varioliformis acuta (PLEVA), insect bites, or mollusca contagiosa. Erythematous papules or papulonodules were the most frequent clinical presentation. Pruritus was specifically mentioned for 20.7% of patients. The main histological subtype was type A in 55.1% of the cases. If analysed, monoclonal TCR rearrangement was found in 76.5% of the skin biopsies. The overall survival rate was 100% with follow up at 5 years available for 33 patients and at 15 years for 8 patients. A development of associated haematological malignancy (HM) occurred in 9.6% of the cases (7/73), including four mycosis fungoides (MF) cases, one primary cutaneous anaplastic large cell lymphoma (pc-ALCL), one systemic ALCL and one case of acute myeloid leukaemia. If we compare incidence rates of cancer with the world 0-19 years old population from 2001-2010, we estimate a significantly higher risk of associated malignancy in general, occurring before the age of 19 years old with incidence rate ratio of 87.49 (CI 86.01-88.99). We report epidemiological data from a large international cohort of children and adolescents with LyP. Overall the prognosis of the disease is good, with excellent survival rates for all patients. Due to increased risk of associated HM, a long-term follow-up should be recommended for LyP patients.

Sections du résumé

BACKGROUND BACKGROUND
Lymphomatoid Papulosis (LyP) is a rare cutaneous T-cell lymphoproliferative disorder. Comprehensive data on LyP in the paediatric population is scarce.
OBJECTIVES OBJECTIVE
To characterize epidemiological, clinical, histopathological, and prognostic features of paediatric LyP.
METHODS METHODS
This was a retrospective, multicentre international cohort study including 87 cases of children and adolescents with LyP diagnosed between 1998 and 2022. Patients aged ≤ 18 years old at disease onset were included. Diagnosis was made in each centre based on clinical-pathological correlation.
RESULTS RESULTS
Eighty-seven patients from 12 centres were included. The mean age at onset was 7.0 years (range 3 months-18 years) with a male to female ratio of 2:1. The mean time between onset of first cutaneous lesions and diagnosis was 1.3 years (range 0-14 years). Initial misdiagnosis concerned 26.4% of patients. Initially, LyP was most often misdiagnosed as Pityriasis lichenoides et varioliformis acuta (PLEVA), insect bites, or mollusca contagiosa. Erythematous papules or papulonodules were the most frequent clinical presentation. Pruritus was specifically mentioned for 20.7% of patients. The main histological subtype was type A in 55.1% of the cases. If analysed, monoclonal TCR rearrangement was found in 76.5% of the skin biopsies. The overall survival rate was 100% with follow up at 5 years available for 33 patients and at 15 years for 8 patients. A development of associated haematological malignancy (HM) occurred in 9.6% of the cases (7/73), including four mycosis fungoides (MF) cases, one primary cutaneous anaplastic large cell lymphoma (pc-ALCL), one systemic ALCL and one case of acute myeloid leukaemia. If we compare incidence rates of cancer with the world 0-19 years old population from 2001-2010, we estimate a significantly higher risk of associated malignancy in general, occurring before the age of 19 years old with incidence rate ratio of 87.49 (CI 86.01-88.99).
CONCLUSIONS CONCLUSIONS
We report epidemiological data from a large international cohort of children and adolescents with LyP. Overall the prognosis of the disease is good, with excellent survival rates for all patients. Due to increased risk of associated HM, a long-term follow-up should be recommended for LyP patients.

Identifiants

pubmed: 38595050
pii: 7643092
doi: 10.1093/bjd/ljae150
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists.

Auteurs

Maël Blanchard (M)

Department of Dermatology, CHUV Lausanne, University of Lausanne, Switzerland.
Division of Dermatology and Venereology, Geneva University Hospitals, Geneva, Switzerland.

Marie-Anne Morren (MA)

Department of Dermatology, CHUV Lausanne, University of Lausanne, Switzerland.

Anne-Marie Busschots (AM)

University Hospitals Leuven, Leuven, Belgium.

Esther Hauben (E)

University Hospitals Leuven, Leuven, Belgium.

Silvia Alberti-Violetti (S)

Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.

Emilio Berti (E)

Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Gianluca Avallone (G)

Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
Department of Medical Sciences, University of Turin, Dermatology Clinic, Turin, Italy.

Gianluca Tavoletti (G)

Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.

Michele Panzone (M)

Department of Medical Sciences, University of Turin, Dermatology Clinic, Turin, Italy.

Pietro Quaglino (P)

Department of Medical Sciences, University of Turin, Dermatology Clinic, Turin, Italy.

Cristiana Colonna (C)

Pediatric Dermatology Unit, dept of clinical sciences and community health, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Rutger C Melchers (RC)

Department of Dermatology, Leiden University Medical Center, Leiden, Netherlands.

Maarten H Vermeer (MH)

Department of Dermatology, Leiden University Medical Center, Leiden, Netherlands.

Robert Gniadecki (R)

Division of Dermatology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.

Christina Mitteldorf (C)

Department of Dermatology, Venereology and Allergology, University Medical Center, Göttingen, Germany.

Janika Gosmann (J)

University Clinic for Dermatology, Johannes Wesling Medical Centre, UKRUB, University of Bochum, Minden, Germany.

Rudolf Stadler (R)

University Clinic for Dermatology, Johannes Wesling Medical Centre, UKRUB, University of Bochum, Minden, Germany.

Constanze Jonak (C)

Medical University of Vienna, Division of General Dermatology, Vienna, Austria.

Meital Oren-Shabtai (M)

Division of Dermatology, Rabin Medical Center, Beilinson Hospital, and Sackler Faculty of Medicine, Tel Aviv University, Israel.

Emmilia Hodak (E)

Division of Dermatology, Rabin Medical Center, Beilinson Hospital, and Sackler Faculty of Medicine, Tel Aviv University, Israel.

Rivka Friedland (R)

Pediatric Dermatology Unit, Schneider Children's Medical Center, and Sackler Faculty of medicine, Tel Aviv University Israel.

Emily Gordon (E)

Department of Dermatology, Columbia University, New York, NY, USA.

Larisa J Geskin (LJ)

Department of Dermatology, Columbia University, New York, NY, USA.

Julia J Scarisbrick (JJ)

Department of Dermatology, University Hospital Birmingham, Birmingham, United Kingdom.

Fatima Mayo Martínez (F)

Department of Dermatology, University Children's Hospital Niño Jesús, Madrid, Spain.

Lucero Noguera Morel (L)

Department of Dermatology, University Children's Hospital Niño Jesús, Madrid, Spain.

Kevin Pehr (K)

Division of Dermatology, Department of Medicine, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

Boyko Amarov (B)

Institute of Statistics and Econometrics, Sofia University "St. Kliment Ohridski", Faculty of Economics and Business Administration, 1113 Sofia, Bulgaria.

Mohamed Faouzi (M)

Centre for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland.

Jan P Nicolay (JP)

Department of Dermatology, Venereology and Allergology, University Medical Center and Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.

Werner Kempf (W)

Department of Dermatology, CHUV Lausanne, University of Lausanne, Switzerland.
Division of Dermatology and Venereology, Geneva University Hospitals, Geneva, Switzerland.

Gabriela Blanchard (G)

Department of Dermatology, CHUV Lausanne, University of Lausanne, Switzerland.
Division of Dermatology and Venereology, Geneva University Hospitals, Geneva, Switzerland.

Emmanuella Guenova (E)

Department of Dermatology, CHUV Lausanne, University of Lausanne, Switzerland.

Classifications MeSH